201 related articles for article (PubMed ID: 29855275)
1. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Quaas A; Waldschmidt D; Alakus H; Zander T; Heydt C; Goeser T; Daheim M; Kasper P; Plum P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Göbel H; Tharun L; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2018 May; 18(1):75. PubMed ID: 29855275
[TBL] [Abstract][Full Text] [Related]
2. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
6. [Conversion Therapy Using Etoposide and Cisplatin Chemotherapy for Liver Metastases from Advanced Gastric Mixed Adenoneuroendocrine Carcinoma - A Case Report].
Inaba Y; Fujita M; Ninomiya R; Hashimoto D
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1488-1490. PubMed ID: 29394677
[TBL] [Abstract][Full Text] [Related]
7. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
8. Ovarian metastases from ileum cancer in a patient with germline EPCAM gene deletion successfully treated with surgical resection and CAPOX chemotherapy: a case report.
Iwata N; Shikama A; Takao W; Hosokawa Y; Itagaki H; Tasaka N; Akiyama A; Ochi H; Minaguchi T; Arita M; Noguchi E; Moriwaki T; Satoh T
BMC Med Genet; 2020 Apr; 21(1):76. PubMed ID: 32272879
[TBL] [Abstract][Full Text] [Related]
9. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Semrau S; Agaimy A; Pavel M; Lubgan D; Schmidt D; Cavallaro A; Golcher H; Grützmann R; Fietkau R
J Med Case Rep; 2019 Mar; 13(1):82. PubMed ID: 30902067
[TBL] [Abstract][Full Text] [Related]
10. [A case of mixed adenoneuroendocrine carcinoma of the transverse colon].
Kusakabe J; Miki A; Kobayashi H; Uryuhara K; Hashida H; Mizumoto M; Kaihara S; Hosotani R; Yamashita D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1826-8. PubMed ID: 25731343
[TBL] [Abstract][Full Text] [Related]
11. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Lowery M; Shah MA; Smyth E; Epstein A; Segal A; Rosengarten O; Isacson R; Drukker L; Keinan A; Rachkiman M; Reissman P; Gabizon A; Kelsen D; O'Reilly EM
J Gastrointest Cancer; 2011 Sep; 42(3):160-4. PubMed ID: 20711688
[TBL] [Abstract][Full Text] [Related]
12. [A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
Sasaki Y; Natsuizaka M; Takano M; Suzuki M; Tsuyuguchi M; Nagasako T; Kawamura N; Kudo M; Tsuda I; Meguro J
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1927-9. PubMed ID: 19920403
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal mixed adenoneuroendocrine carcinoma (MANEC): An immunohistochemistry study of 13 microsatellite stable cases.
Gurzu S; Fetyko A; Bara T; Banias L; Butiurca VO; Bara T; Tudorache V; Jung I
Pathol Res Pract; 2019 Dec; 215(12):152697. PubMed ID: 31704155
[TBL] [Abstract][Full Text] [Related]
14. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
15. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
16. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
17. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
[TBL] [Abstract][Full Text] [Related]
18. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A; Heydt C; Waldschmidt D; Alakus H; Zander T; Goeser T; Kasper P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2019 Feb; 19(1):21. PubMed ID: 30717682
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
20. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP
Future Oncol; 2017 Feb; 13(4):307-320. PubMed ID: 27739325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]